Bristol-Myers Squibb (NYSE:BMY) is joining forces with Illumina (NSDQ:ILMN) to develop and commercialize diagnostic tests to support Bristol’s portfolio of cancer drugs. The companies announced last week that they plan to develop an assay to measure predictive genomic biomarkers, like tumor mutation burden, that could help doctors identify patients that will benefit from Bristol’s immunotherapies. Get the full […]
Illumina, Loxo Oncology partner for next-gen pan-cancer companion diagnostics
Illumina (NSDQ:ILMN) and Loxo Oncology (NSDQ:LOXO) are teaming up to develop a multi-gene panel for broad tumor profiling. The two companies ultimately hope to sell a next-gen sequencing-based companion diagnostic that will boast a pan-cancer indication. Illumina and Loxo plan to seek approval for a version of Illumina’s TruSight Tumor 170 test as a companion […]
Skyline Medical to take 20% stake in Helomics, license Illumina’s gene sequencing tech
Fresh from its purchase of a 20% stake in joint venture partner Helomics, Skyline Medical (NSDQ:SKLN) said today that it inked a deal to license the MiSeqDx next-generation sequencing technology from Illumina (NSDQ:ILMN). Yesterday Minneapolis-based Skyline said it agreed to buy a lump of convertible shares representing 20% of Helomics, in exchange for 1.1 million newly issued SKLN shares, which […]
Philips, Illumina to launch precision medicine cancer program with Navican
Royal Philips (NYSE:PHG) and Intermountain Healthcare company Navican inked an agreement today to launch a precision health informatics solution aimed at improving outcomes for late stage cancer patients. The program is slated to leverage Navican‘s TheraMap Precision Cancer Care services and Philips’ IntelliSpace Genomics platform, which uses Illumina‘s next-gen genomic sequencing technologies. At Utah-based Intermountain Healthcare’s […]
Illumina, Novogene ink development deal for next-gen sequencing tech
Illumina (NSDQ:ILMN) and genomic service company Novogene said today they entered into an agreement to jointly develop advanced clinical applications for reproductive health and oncology based on next-generation sequencing technology. The collaboration will focus on providing advanced, integrated sequencing solutions to the clinical market, the company said. The 2 companies are slated to work together to create […]
Illumina unveils highly sought $1,000 genome system | MassDevice.com On Call
MASSDEVICE ON CALL — California-based lifesciences firm Illumina’s (NSDQ:ILMN) this week unveiled that it had achieved the highly sought $1,000 mark for human DNA sequencing.
Dick Cheney as a road map for heart tech | MassDevice.com On Call
MASSDEVICE ON CALL — Former Vice President Dick Cheney’s long-running battle with heart disease also traces the evolution of cardiovascular medical technologies.
The New York Times traced Cheney’s heart history as it correlated to important milestones in medicine, from his 1st heart attack at age 37 to the heart transplant he received last month.
Cheney was one of the relatively early recipients of quadruple bypass surgery in 1988 and a cardiac stent in 2000.
Illumina launches “poison pill” against Roche’s takeover bid | MassDevice.com On Call
MASSDEVICE ON CALL —Illumina’s (NSDQ:ILMN) board of directors adopted a "poison pill" strategy in response to a hostile takeover bid by Roche (PINK:RHHBY).
Illumina adopted a rights agreement which allows shareholders other than the a bidder to buy additional shares at a discounted price, potentially deterring would-be bidders by increasing costs.
BioMimetic slashes 25% of jobs following FDA delays | MassDevice.com On Call
MASSDEVICE ON CALL — BioMimetic Therapeutics (NSDQ:BMTI) cut 25% of its workers in hopes of saving some cash in focusing on getting FDA pre-market approval for its Augment bone graft.
The federal watchdog agency’s advisory panel recommended approving the treatment in May 2011, after releasing a dim summary of the pre-market approval application that sunk BMTI shares by more than 35%.
Covidien launches $2 billion stock repurchase program
Covidien Plc.’s (NYSE:COV) board of directors approved a $2 billion stock repurchase program today.
"The board’s approval of this share repurchase program reflects its confidence in the continued growth of Covidien’s business, our sustainable free cash flow and our commitment to enhance shareholder value," president & CEO José Almeida said in a press release.
MassDevice Network
@MassDevice
LinkedIn
YouTube